Exportação concluída — 

PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence

Bibliographic Details
Main Author: Lapa, Paula
Publication Date: 2016
Other Authors: Silva, Rodolfo, Saraiva, Tiago, Figueiredo, Arnaldo, Ferreira, Rui, Costa, Gracinda, Lima, João Pedroso
Format: Article
Language: por
eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056
Summary: Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy.
id RCAP_094732fd12aea70ae6b8aeef63e4c1e8
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/7056
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical RecurrencePET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva BioquímicaFluorocholinePositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticals.FluorocolinaNeoplasias da PróstataRadiofármacosTomografia por Emissão de Positrões.Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy.Introdução: No carcinoma da próstata, é frequente, após terapêutica com intuito curativo, ocorrer recidiva bioquímica. O objectivo deste trabalho foi avaliar o impacto da PET/CT com fluorocolina-F18 no restadiamento e orientação destes doentes e analisar a influência, da estratificação de risco, dos valores do PSA e da terapêutica de supressão hormonal, na sensibilidade da técnica. Material e Métodos: Análise retrospectiva de 107 doentes com carcinoma da próstata em recidiva bioquímica que realizaram PET/CT com fluorocolina-F18 no nosso hospital, entre dezembro de 2009 e maio de 2014. Resultados: A sensibilidade global foi de 63,2% sendo 80,0% quando PSA > 2 ng/mL. Foi possível identificar doença à distância em 28% dos doentes. A sensibilidade aumentou de 40,0% em doentes de risco baixo e intermédio para 55,2% em doentes de alto risco. Sem terapêutica de supressão hormonal, a sensibilidade foi de 61,8% enquanto no grupo sob essa terapêutica, foi de 67,7%. Discussão: A PET/CT com fluorocolina-F18 forneceu informações relevantes, mesmo em doentes com baixos valores do PSA, contudo, com incremento significativo da sensibilidade nos doentes com PSA >2 ng/mL. A sensibilidade foi superior nos doentes de alto risco comparativamente com os de risco baixo e intermédio, contudo, sem uma diferença estatisticamente significativa. A terapêutica de supressão hormonal parece não influenciar a captação de Fluorocolina-F18 nos doentes resistentes à castração. Conclusões: Neste estudo, a PET/CT com fluorocolina-F18 apresentou bons resultados no restadiamento de doentes com carcinoma da próstata em recidiva bioquímica, distinguindo entre doença loco-regional e sistémica, informação com importantes consequências na definição da estratégia terapêutica.Ordem dos Médicos2016-03-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfimage/jpegimage/pngimage/pngimage/pngimage/pngimage/pngimage/pnghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056oai:ojs.www.actamedicaportuguesa.com:article/7056Acta Médica Portuguesa; Vol. 29 No. 3 (2016): March; 182-192Acta Médica Portuguesa; Vol. 29 N.º 3 (2016): Março; 182-1921646-07580870-399Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPporenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4617https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4777https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/7943https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8098https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8220https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8221https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8222https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8223https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8224https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8225Direitos de Autor (c) 2016 Copyright © Ordem dos Médicosinfo:eu-repo/semantics/openAccessLapa, PaulaSilva, RodolfoSaraiva, TiagoFigueiredo, ArnaldoFerreira, RuiCosta, GracindaLima, João Pedroso2022-12-20T11:05:05Zoai:ojs.www.actamedicaportuguesa.com:article/7056Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:40:46.217036Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
PET/CT com Fluorocolina-F18 em Doentes com Carcinoma da Próstata em Recidiva Bioquímica
title PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
spellingShingle PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
Lapa, Paula
Fluorocholine
Positron-Emission Tomography
Prostatic Neoplasms
Radiopharmaceuticals.
Fluorocolina
Neoplasias da Próstata
Radiofármacos
Tomografia por Emissão de Positrões.
title_short PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
title_full PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
title_fullStr PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
title_full_unstemmed PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
title_sort PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence
author Lapa, Paula
author_facet Lapa, Paula
Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Lima, João Pedroso
author_role author
author2 Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Lima, João Pedroso
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Lapa, Paula
Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Lima, João Pedroso
dc.subject.por.fl_str_mv Fluorocholine
Positron-Emission Tomography
Prostatic Neoplasms
Radiopharmaceuticals.
Fluorocolina
Neoplasias da Próstata
Radiofármacos
Tomografia por Emissão de Positrões.
topic Fluorocholine
Positron-Emission Tomography
Prostatic Neoplasms
Radiopharmaceuticals.
Fluorocolina
Neoplasias da Próstata
Radiofármacos
Tomografia por Emissão de Positrões.
description Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity. Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014. Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%. Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration. Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy.
publishDate 2016
dc.date.none.fl_str_mv 2016-03-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056
oai:ojs.www.actamedicaportuguesa.com:article/7056
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/7056
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4617
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/4777
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/7943
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8098
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8220
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8221
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8222
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8223
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8224
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056/8225
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2016 Copyright © Ordem dos Médicos
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2016 Copyright © Ordem dos Médicos
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
image/jpeg
image/png
image/png
image/png
image/png
image/png
image/png
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 29 No. 3 (2016): March; 182-192
Acta Médica Portuguesa; Vol. 29 N.º 3 (2016): Março; 182-192
1646-0758
0870-399X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591117055000576